captured official filings
Evofem Biosciences, Inc.
Automatically organized from the issuer’s official SEC submissions index. This brief is the starting evidence layer for buyer, FA, legal and broker-dealer review—not a legal conclusion or safety rating.
captured official filings
captured official filings
captured official filings
captured official filings
What to review next
Rules are applied to retained SEC filing types in this issuer record. They prioritize reading work; they are not ratings or conclusions.
No retained filing in the latest 16 records matched the current priority rules. This is not clearance; review the official timeline for context.
One evidence index instead of a manual filing hunt.
It groups recent reporting, registration/offer, ownership and governance filings, preserves the SEC source link and keeps a reusable chronology in the issuer’s record.
What teams can pay to automate next.
Cross-version text comparison, monitored alerts, change-specific diligence questions, CSV/PDF exports and a shared deal-team brief are the professional workflow built on this public evidence layer.
Official comparison files are temporarily unavailable
Both filings are identified, but their source text could not be read for comparison yet. Use the two SEC links below or retry shortly.
What to verify next
Generated from retained official filing types and chronology. This is a work sequence, not legal, accounting, compliance, investment or transaction advice.
- Current disclosure path (56 retained)
Open the retained current reports and identify the reported item, effective date and later update. - Financial & ownership record (20 retained)
Review periodic financial, ownership and governance records in their original filing context.
A dated Download Edition preserves this source-linked view for a project file.
Know what the paid record contains.
This is a dated working copy of the public issuer record, organized for a project file—not a separate data feed or an opinion.
Best when you need to preserve what was visible, attach it to a project, or hand a source-linked record to a colleague, counsel or internal reviewer.
Turn this issuer page into a project-file deliverable.
US$29 one time. For the moment you need to preserve the official record, hand it to a colleague or attach it to a deal file. No subscription, account or recurring charge. Download begins in this browser after payment is verified.
- Source-linked filing chronology and registration path
- Filing-change radar plus financing, legal, tax/lien and regulatory disclosure cues
- Official-source index for project-file archiving and downloadable CSV export
Pay once · verified PayPal checkout · immediate HTML and CSV delivery.
Save this source-linked record
Download a printable HTML snapshot of the current public-record timeline and change view. A one-time download unlocks a saveable issuer record. Official sources remain controlling.
Specific public-record cues, separated from generic language
Reads selected SEC filing text by sentence. Contents-page labels, generic risk language and allocation discussion are excluded; historical financing language is kept separate.
- FINANCING
01 Entry into a Material Definitive Agreement Amendment to Securities Purchase Agreement On October 9, 2026 (the “Effective Date”), Evofem Biosciences, Inc.
8-K · 2026-10-15 · official SEC source ↗ - FINANCING
(together, “Adjuvant”) entered into a fifth amendment (the “Fifth Amendment”) to the Securities Purchase Agreement dated as of October 14, 2020, as amended (the “SPA”, pursuant to which Adjuvant purchased from the Company certain convertible promissory notes (the “Notes”).
8-K · 2026-10-15 · official SEC source ↗ - FINANCING
The Fifth Amendment amends certain provisions within the Securities Purchase Agreement including updating the date that the Notes will be payable in full to the earlier of (a) December 1, 2026, (b) at the election of Adjuvant, the date of a consummation of a Change of Control (as defined in the Securities Purchase Agreement), and (c) the date of any acceleration of the Notes in accordance with Section 8 (the “Maturity Date”, as per the Securities Purchase Agreement).
8-K · 2026-10-15 · official SEC source ↗ - FINANCING
1 Fifth Amendment to Securities Purchase Agreement dated as of October 9, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
8-K · 2026-10-15 · official SEC source ↗
Scope: automated text screening of selected SEC filings only. Each cue requires review of the linked filing; it does not confirm a claim, legal status, tax status, financing completion or current issuer condition.
Financing, legal and disclosure cues
This screen counts source documents with a reading cue, never the number of underlying events. A cue may be generic risk language; open the cited SEC source before drawing any conclusion.
View screened SEC sources (4)
Coverage boundary: this is a keyword screen of selected SEC filings only. It is not a court-docket search, tax-compliance review, lien clearance, sanctions screen, adverse-media search or a complete count of financings. A zero result means no matching term in the readable documents screened—not that the underlying issue is absent. Verify each cue in the linked official filing and use the appropriate independent professionals.
Official filing path for financing review
Registration, amendment, prospectus, shelf and current-report nodes are organized here as a reading path. Use the SEC source for terms, status and materiality.
- 8-KCurrent report — review financing contextOpen SEC source →
- 8-KCurrent report — review financing contextOpen SEC source →
- 8-KCurrent report — review financing contextOpen SEC source →
- 8-KCurrent report — review financing contextOpen SEC source →
- 8-KCurrent report — review financing contextOpen SEC source →
- 8-KCurrent report — review financing contextOpen SEC source →
- 8-KCurrent report — review financing contextOpen SEC source →
- 8-KCurrent report — review financing contextOpen SEC source →
- 8-KCurrent report — review financing contextOpen SEC source →
- 8-KCurrent report — review financing contextOpen SEC source →
- 8-KCurrent report — review financing contextOpen SEC source →
- 8-KCurrent report — review financing contextOpen SEC source →
- 8-KCurrent report — review financing contextOpen SEC source →
- 8-KCurrent report — review financing contextOpen SEC source →
- 8-KCurrent report — review financing contextOpen SEC source →
- 8-KCurrent report — review financing contextOpen SEC source →
- 8-KCurrent report — review financing contextOpen SEC source →
- 8-KCurrent report — review financing contextOpen SEC source →
- 8-KCurrent report — review financing contextOpen SEC source →
- 8-KCurrent report — review financing contextOpen SEC source →
- 8-KCurrent report — review financing contextOpen SEC source →
- 8-KCurrent report — review financing contextOpen SEC source →
Interpretation boundary: filing counts are not financing-round counts, proceeds, closing status or current capitalization. A registration, prospectus or report can relate to different purposes; use the linked official filing and appropriate advisers to verify each event.
What the latest offering documents say
Candidate sentence excerpts from readable official SEC filing text. This provides a fast reading layer for offering structure and terms; it is not a normalized term sheet or a transaction conclusion.
Offering structure
Candidate language describing the securities or registration structure.
“333-267591 3,336,730 Shares of Common Stock Issuable upon Exercise of Outstanding Warrants 7,642,038 Shares of Common Stock Issuable upon Conversion of Senior Subordinated Convertible Notes This prospectus relates to the resale from time to time, by the Selling Securityholders identified in this prospectus under the caption “Selling Securityholders” of up to 3,336,730 shares of our common stock which are issuable u”424B3 · 2023-08-14 · Open SEC source →
Shares / price
Candidate language about shares, units or offering-price terms.
“333-267591 3,336,730 Shares of Common Stock Issuable upon Exercise of Outstanding Warrants 7,642,038 Shares of Common Stock Issuable upon Conversion of Senior Subordinated Convertible Notes This prospectus relates to the resale from time to time, by the Selling Securityholders identified in this prospectus under the caption “Selling Securityholders” of up to 3,336,730 shares of our common stock which are issuable u”424B3 · 2023-08-14 · Open SEC source →
Use of proceeds
Candidate language describing stated proceeds or intended use.
“See “Use of Proceeds” beginning on page 59 and “Plan of Distribution” beginning on page 130 of this prospectus for more information.”424B3 · 2023-08-14 · Open SEC source →
Convertible / warrant terms
Candidate language about conversion, warrants or related instruments.
“5 million, respectively (the February and March 2023 Notes), and (ii) warrants to purchase an aggregate 553,846, 240,000, and 215,384 shares of common stock, respectively (the February and March 2023 Warrants and collectively, the February and March 2023 Offerings).”424B3 · 2023-08-14 · Open SEC source →
View offering documents screened (2)
Extraction boundary: wording can be incomplete, duplicated, conditional or superseded by later filings. The system does not calculate proceeds, share counts, dilution or closing status from these excerpts. Verify every term in the linked official SEC filing.
Captured filing chronology
- 8-KReporting & material eventsOpen SEC filing →
- 10-QReporting & material eventsOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 10-QReporting & material eventsOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 10-QReporting & material eventsOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 10-KReporting & material eventsOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 10-QReporting & material eventsOpen SEC filing →
- DEF 14AGovernanceOpen SEC filing →
- PRE 14AGovernanceOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 10-QReporting & material eventsOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- DOther official filingOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 10-QReporting & material eventsOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- DOther official filingOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 10-K/AReporting & material eventsOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 10-KReporting & material eventsOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 10-QReporting & material eventsOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- PRE 14AGovernanceOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- DOther official filingOpen SEC filing →
- DOther official filingOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 10-QReporting & material eventsOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
Only official SEC submission-index facts are automated here. The brief does not determine shell status, beneficial ownership, capitalization, legal compliance, valuation, active-trading status or transaction suitability. Those questions require the appropriate source documents and independently retained professionals.